Merrimack Pharmaceuticals
(NASDAQ) MACK
This security has been delisted. This page is retained for historical reference.
MACK News
3 Stocks Begging for a Buyout
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowMACK Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-6%
Return on Capital
-12%
Return on Assets
-6%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$2.18M
EBITDA
$1.01M
Operating Cash Flow
$1.52M
Capital Expenditure
$0.00
Free Cash Flow
$1.52M
Cash & ST Invst.
$18.88M
Total Debt
$0.00
Merrimack Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
0
N/A
Net Income
$23.63M
-24773.7%
EBITDA
$669.00K
+7.7%
Quarterly Fundamentals
Net Cash
$244.11M
+1158.2%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-6.15%
N/A
Return on Invested Capital
-11.61%
N/A
Free Cash Flow
$1.31M
-269.1%
Operating Cash Flow
$1.31M
-269.1%